Series A · Healthtech · Munich, Germany · Founded 2018 · 27–35 employees
Mybacs is a biotechnology company specializing in synbiotic dietary supplements designed to support gut health and the human microbiome. Founded in 2018, the company has developed scientifically-backed products including Travel and Daily probiotic supplements that combine probiotics, prebiotics, vitamins, and minerals. The startup completed its Series A funding round in 2023, raising 5.6 million euros led by naturalX Health Ventures, with participation from WENVEST Capital, SevenVentures, and existing investors Global Founders Capital and Joyance Partners. Mybacs operates as a direct-to-consumer brand focusing on modern health needs with both scientific rigor and aesthetic appeal.
No open roles listed right now.